Skip to main content

Table 2 Prognostic factors for overall survival of patients with invasive micropapillary breast cancer

From: Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database

Characteristic Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age
 ≤ 50 1.000    1.000   
 51–64 0.783 0.515–1.193 0.255 0.899 0.585–1.382 0.628
 ≥ 65 1.929 1.327–2.805 0.001 2.494 1.657–3.752 < 0.001
Race
 White 1.000   
 African American 1.001 0.667–1.503 0.995
 Other 0.591 0.277–1.257 0.172
Sex
 Female 1.000   
 Male 1.130 0.465–2.740 0.787
Charlson–Deyo comorbidity score
 0 1.000    1.000   
 1 1.871 1.311–2.671 0.001 1.513 1.049–2.183 0.027
 ≥ 2 3.349 1.898–5.910 < 0.001 2.200 1.217–3.978 0.009
Clinical T stage
 1 1.000    1.000   
 2 2.052 1.507–2.794 < 0.001 1.888 1.340–2.660 < 0.001
 3 2.345 1.504–3.656 < 0.001 2.230 1.314–3.784 0.003
 4 3.649 2.222–5.993 < 0.001 2.851 1.602–5.073 < 0.001
Clinical N stage
 0 1.000    1.000   
 1 1.546 1.122–2.130 0.008 1.194 0.771–1.850 0.426
 2 3.832 2.390–6.147 < 0.001 2.009 1.099–3.676 0.024
 3 1.825 0.852–3.908 0.122 0.925 0.292–2.184 0.859
Surgery
 Lumpectomy 1.000    1.000   
 Mastectomy 1.373 1.040–1.812 0.025 1.027 0.751–1.404 0.869
Radiotherapy
 Yes 1.000    1.000   
 No 1.755 1.336–2.307 < 0.001 2.344 1.711–3.210 < 0.001
Histologic grade
 Well differentiated 1.000   
 Moderately differentiated 0.981 0.558–1.723 0.946
 Poorly differentiated/undifferentiated 1.457 0.831–2.552 0.189
 Not reported 0.721 0.291–1.788 0.481
ER status
 Positive 1.000    1.000   
 Negative 2.245 1.629–3.113 < 0.001 2.804 1.827–4.305 < 0.001
 Unknown 0.704 0.260–1.906 0.490 0.585 0.211–1.626 0.304
PR status
 Positive 1.000    1.000   
 Negative 1.6501 1.223–2.227 0.001 1.586 1.166–2.156 0.003
 Unknown 0.731 0.298–1.788 0.492 0.825 0.335–2.045 0.677
HER2 status
 Positive 1.000   
 Negative 1.021 0.604–1.728 0.937
 Unknown 0.857 0.503–1.460 0.570
Chemotherapy
 Yes 1.000   
 No 0.914 0.679–1.230 0.552
 Not reported 1.314 0.874–1.977 0.189
Hormonal therapy
 Yes 1.000    1.000   
 No 1.526 1.134–2.054 0.005 0.789 0.538–1.158 0.227
 Not reported 1.296 0.745–0.254 0.358 1.013 0.567–1.810 0.965
Lymph nodes involved
 0 1.000    1.000   
 1–3 0.971 0.656–1.438 0.883 1.087 0.700–1.687 0.711
 4 or more 2.438 1.750–3.398 < 0.001 2.292 1.413–3.719 0.001
 Unknown 1.823 1.174–0.828 0.007 1.507 0.962–2.361 0.073
  1. OS overall survival, HR hazard ratio, CI confidence interval, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2